Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. (20th October 2021)

• Record Type: Journal Article
• Authors: Berek, Jonathan S.; Renz, Malte; Kehoe, Sean; Kumar, Lalit; Friedlander, Michael
• Other Names: Kehoe Sean guestEditor.; Bhatla Neerja guestEditor.
• Is Part Of: International journal of gynaecology and obstetrics. Volume 155(2021)Supplement 1
• Page Start: 61
• Page End: 85
• Publication Date: 2021-10-20
• Subjects: cancer staging -- chemotherapy -- fallopian tube -- FIGO Cancer Report -- ovarian -- ovary -- peritoneum; Gynecology -- Periodicals; Obstetrics -- Periodicals; Electronic journals; 618
• DOI: 10.1002/ijgo.13878
• Languages: English
• ISSNs: 0020-7292

Abstract

Abstract: In 2014, FIGO's Committee for Gynecologic Oncology revised the staging of ovarian cancer, incorporating ovarian, fallopian tube, and peritoneal cancer into the same system. Most of these malignancies are high‐grade serous carcinomas (HGSC). Stage IC is now divided into three categories: IC1 (surgical spill); IC2 (capsule ruptured before surgery or tumor on ovarian or fallopian tube surface); and IC3 (malignant cells in the ascites or peritoneal washings). The updated staging includes a revision of Stage IIIC based on spread to the retroperitoneal lymph nodes alone without intraperitoneal dissemination. This category is now subdivided into IIIA1(i) (metastasis ≤10 mm in greatest dimension), and IIIA1(ii) (metastasis >10 mm in greatest dimension). Stage IIIA2 is now "microscopic extrapelvic peritoneal involvement with or without positive retroperitoneal lymph node" metastasis. This review summarizes the genetics, surgical management, chemotherapy, and targeted therapies for epithelial cancers, and the treatment of ovarian germ cell and stromal malignancies. Synopsis: The 2014 FIGO staging incorporates ovarian, fallopian tube, and peritoneal cancer into the same system. This review summarizes the updated staging and treatment of these malignancies.